OncoCyte (NYSEAMERICAN:OCX) Announces Quarterly Earnings Results
OncoCyte (NYSEAMERICAN:OCX) posted its earnings results on Wednesday. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03), MarketWatch Earnings reports.
Shares of OCX stock traded up $0.01 on Thursday, reaching $1.38. The company’s stock had a trading volume of 19,693 shares, compared to its average volume of 502,299. OncoCyte has a 12-month low of $1.20 and a 12-month high of $3.51.
Several equities research analysts have issued reports on OCX shares. Chardan Capital downgraded OncoCyte from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $7.75 to $2.00 in a research report on Tuesday, June 30th. Zacks Investment Research upgraded OncoCyte from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research report on Wednesday, July 15th. Lake Street Capital dropped their target price on OncoCyte from $6.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, June 30th. Piper Sandler downgraded OncoCyte from an “overweight” rating to a “neutral” rating in a research report on Tuesday, June 30th. Finally, Benchmark dropped their target price on OncoCyte from $7.00 to $6.00 and set a “speculative buy” rating on the stock in a research report on Thursday. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $4.17.
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.
Recommended Story: Hedge Funds Explained
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.